|
Dr. Protopopova joined Sequella in 1999 as a Senior Scientist responsible for identifying new TB drugs. She was promoted to Director of Chemistry in 2001, and was named Vice President of Drug Discovery in 2006. From 2000 to 2006, she played a key role in advancing the Sequella drug candidate SQ109 from discovery in 2000 to IND-directed preclinical studies and into clinical development in 2006. She now oversees drug discovery and pre-clinical research programs, including toxicology, chemistry, pharmacology, and biology. Her scientific career spans over 20 years, including work experience in both the United States and Russia. She worked at the National Institutes of Health (NIH) under a Sequella CRADA, where she initiated a combinatorial chemistry program for discovery of new antibiotics that was moved to Sequella in 2000. Prior to her employment at Sequella, she worked with Regis Technologies in IL to develop new chiral catalysts and proprietary combinatorial chemistry technology for chromatographic applications. While in Russia, Dr. Protopopova was involved in a National Program for the development of novel technologies for production of pyrethroid insecticides in the (former) USSR. Dr. Protopopova has authored several issued patents, and over 40 publications in leading chemistry and scientific journals. She holds a Ph.D. from Zelinskii Institute of Organic Chemistry of the Russian Academy of Sciences and earned a M.S. from Moscow State University. | 